sur BioVersys AG
BioVersys and Hackensack Meridian Health Collaborate on NTM Research
BioVersys AG has announced a strategic collaboration with Hackensack Meridian Health (HMH) to enhance its Ansamycin Chemistry platform and research into non-tuberculous mycobacteria (NTM) diseases. This exclusive agreement aims to develop ansamycin antimicrobial candidates into viable treatments.
HMH, a leading healthcare network in the US, will contribute its expertise through its Center for Discovery and Innovation. NTMs are a significant concern, particularly for patients with chronic lung conditions like cystic fibrosis. BioVersys aims to address these challenges by leveraging advanced lead molecules and building on its existing research efforts.
The collaboration will involve shared development of ansamycin candidates, with HMH receiving upfront payments and potential royalties. This partnership underscores BioVersys' commitment to advancing novel antibacterial treatments for life-threatening infections.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioVersys AG